Skip to main content
. 2024 Mar 22;38(5):458–470. doi: 10.1177/02698811241237870

Figure 2.

Figure 2.

QIDS-SR16 scores across time for discontinuers and unmedicated patients separately, after removing the effect of individual differences as captured by a random intercept in a mixed linear model. Thick lines connect mean values, and boxes show medians, 25 and 75 percentiles. Among unmedicated patients, greater decreases from baseline were seen in the psilocybin group compared with the escitalopram group at all timepoints except week 2. Among discontinuers, being in different treatment arms did not significantly add to the model.